Search

everythinglearnresearchcommunity

for

Search:↓

Micrografts are a safe and effective treatment for hair loss in both men and women.

The demineralized bone matrix scaffold is better for cell attachment than the mineralized bone allograft.

Hair transplantation is safe and effective for children with scar-related hair loss.

The study found that the quality of cord blood units remains consistent before freezing and after thawing, indicating that attached tube segments reliably represent the graft's properties.

Transplanting a person's own hair can heal chronic wounds in certain skin conditions.

The humanized AA mouse model is better for testing new alopecia areata treatments.

The combination of mitoxantrone, etoposide, and prednisolone is effective for treating relapsed lymphoma with manageable side effects.

Alopecia areata involves unique activation of certain immune cells.

Using regulatory T cells and Rapamycin together improves chronic graft-versus-host disease treatment outcomes in mice.

RCS-01 cell therapy is safe and improves skin gene expression.

BST2 is a key marker for hair loss disease alopecia areata.

Certain CD8+ T cells attack hair follicles in alopecia areata, suggesting they could be targeted for treatment.

Injecting a cell suspension from hair follicles increased hair density in a balding patient.

Careful planning and patient counseling can lead to excellent hair transplant results, often in one or two sessions.

Aldesleukin can treat certain cancers and increase HIV patient CD4+ counts but often causes severe side effects.

Both induced and spontaneous AA lymphocytes can cause alopecia areata in mice.

Higher TGF-β signaling may increase skin cancer risk in organ transplant recipients.

Some patients developed hair loss after islet cell transplant possibly due to their immune-suppressing medications.

Stem cell therapies show promise for hair regrowth in androgenetic alopecia.

Hair from balding and non-balding areas regrows similarly on mice.

Poor response to topical immunotherapy in alopecia areata patients is linked to impaired cell responses.

Rb-bFGF improves hair transplant results and patient satisfaction with fewer complications.

Immunochemotherapy successfully treated neutropenia in a patient with Waldenström's macroglobulinemia.

Serum from alopecia patients does not stop hair growth in grafted skin on mice.

Alopecia areata involves specific immune cells, offering potential treatment targets.

Nestin-expressing blood vessels help skin transplants survive and heal.

Alopecia areata patients have more activated T cells in their blood, which may help in developing treatments.

A patient with leukemia/lymphoma also had multiple autoimmune diseases, suggesting a link between them.

A humanized CXCL12 antibody may delay and treat alopecia areata by altering the immune response.

Epigenetic changes in blood cells may contribute to alopecia areata.